Evaluation of macular vasculature in schizophrenia compared to healthy subjects

Document Type : Original Article

Authors

1 Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Eye Research Center, Mashhad University of medical Sciences, Mashhad, Iran

3 Retina research center, Mashhad University of Medical Sciences

4 Department of Preventive and Community Medicine- Faculty of Medicine- Mashhad University of Medical Sciences

5 Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Purpose: This study aims to evaluate the macular thickness and vasculature changes with a readily available method named Optical Coherence Tomography Angiography (OCT-A) in patients with schizophrenia compared to healthy people.
Methods: The present cross-sectional study was conducted in 2019 at the Ibn-e-Sina Psychiatry Hospital of Mashhad. Twenty-Two cases of schizophrenia, treated with risperidone and age-matched 22 healthy individuals, were participated in the study. The disease severity assessment was scaled with the Positive And Negative Syndrome Scale (PANSS) test. All participants underwent complete ophthalmic examination and OCTA imaging.
Results: There was a statistically significant difference for fovea full-thickness (P=0.021) and parafovea full retinal thickness (P=0.029) between schizophrenic and healthy subjects. Fovea full retinal thickness, parafovea full retinal thickness, Fovea vessel density, and parafovea vessel density in patients with markedly ill schizophrenia, were significantly lower than the moderately ill subgroup (P=0.027, P=0.017, P=0.034, P=0.015).
Conclusion: We proposed that retinal neural and vascular tissues can be used as a research model in schizophrenia. We found a significantly lower foveal and parafoveal thickness in patients with schizophrenia than in healthy subjects, but it does not necessarily mean that there is a degenerative process in the pathogenesis of schizophrenia.

Keywords

References

 1.Kaplan BJ. Kaplan and sadock’s synopsis of
psychiatry. Behavioral sciences/clinical psychiatry.
Tijdschrift voor Psychiatrie 2016;58(1):609.
2.Woods BT. Is schizophrenia a progressive
neurodevelopmental disorder? Toward a unitary
pathogenetic mechanism. American Journal of
Psychiatry 1998;155(12):1661-1670.
3.Gaebel W, Riesbeck M, Larach VW, Falkai P,
Zielasek J. Trends in Schizophrenia diagnosis and
treatment. Advances in Psychiatry: Springer; 2019. p
603-619.
4.Sullivan PF. How good were candidate gene guesses in
schizophrenia genetics? Biological Psychiatry
2017;82(10):696.
5.Heinz A, Borgwardt S, DeLisi LE. Neuroimaging of
Neurotransmitter Alterations in Schizophrenia and Its
Relevance for Negative Symptoms. Neuroimaging of
Schizophrenia and Other Primary Psychotic Disorders:
Springer; 2019. p 157-169.
6.Stahl SM. Beyond the dopamine hypothesis of
schizophrenia to three neural networks of psychosis:
dopamine, serotonin, and glutamate. CNS Spectr
2018;23(3):187-191.
Naghib M et al.
Razavi Int J Med. 2022; 10(2):e1108. 27
7.Gold MS, Blum K, Febo M, Baron D, Modestino EJ,
Elman I, Badgaiyan RD. Molecular role of dopamine in
anhedonia linked to reward deficiency syndrome (RDS)
and anti- reward systems. Front Biosci (Schol Ed)
2018;10:309-325.
8.Riordan AJ, Schaler AW, Fried JB, Paine TA,
Thornton JE. Estradiol and luteinizing hormone reverse
memory loss in phencyclidine model of schizophrenia:
Evidence for hippocampal GABA action. bioRxiv
2017:207159.
9.Shenton ME, Dickey CC, Frumin M, McCarley RW. A
review of MRI findings in schizophrenia. Schizophr Res
2001;49(1-2):1-52.
10.Chu EM-Y, Kolappan M, Barnes TR, Joyce EM, Ron
MA. A window into the brain: an in vivo study of the
retina in schizophrenia using optical coherence
tomography. Psychiatry Research: Neuroimaging
2012;203(1):89-94.
11.Kay SR, Fiszbein A, Opler LA. The positive and
negative syndrome scale (PANSS) for schizophrenia.
Schizophr Bull 1987;13(2):261-76.
12.Leucht S, Kane JM, Kissling W, Hamann J, Etschel
E, Engel RR. What does the PANSS mean? Schizophr
Res 2005;79(2-3):231-8.
13.Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui
M. Ocular indicators of Alzheimer's: exploring disease in
the retina. Acta Neuropathol 2016;132(6):767-787.
14.Lee JY, Ahn J, Oh S, Shin JY, Kim YK, Nam H, Jeon
B. Retina thickness as a marker of neurodegeneration in
prodromal lewy body disease. Mov Disord
2020;35(2):349-354.
15.Ascaso FJ, Laura C, Quintanilla MÁ, Gutiérrez Galve
L, López-Antón R, Cristóbal JA, Lobo A. Retinal nerve
fiber layer thickness measured by optical coherence
tomography in patients with schizophrenia: a short
report. The European journal of psychiatry
2010;24(4):227-235.
16.Lee WW, Tajunisah I, Sharmilla K, Peyman M,
Subrayan V. Retinal nerve fiber layer structure
abnormalities in schizophrenia and its relationship to
disease state: evidence from optical coherence
tomography. Invest Ophthalmol Vis Sci
2013;54(12):7785-92.
17.Mota M, Pego P, Klut C, Pires G, Maia T. Retina and
Schizophrenia. J Eye Cataract Surg 2017;3:21.
18.Yilmaz U, Kucuk E, Ulgen A, Ozkose A, Demircan
S, Ulusoy DM, Zararsiz G. Retinal nerve fiber layer and
macular thickness measurement in patients with
schizophrenia. Eur J Ophthalmol 2016;26(4):375-8. 
Razavi International Journal of Medicine
Volume 10, Issue 2
April 2022
Pages 23-27

Files

Share

How to cite

Statistics